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Abstract
Diabetic peripheral neuropathy (DPN) is the most common chronic
complication of diabetes. It poses a significant challenge for clinicians as it is
often diagnosed late when patients present with advanced consequences such
as foot ulceration. Autonomic neuropathy (AN) is also a frequent and
under-diagnosed complication unless it is overtly symptomatic. Both somatic
and autonomic neuropathy are associated with increased mortality. Multiple
clinical trials have failed because of limited efficacy in advanced disease,
inadequate trial duration, lack of effective surrogate end-points and a lack of
deterioration in the placebo arm in clinical trials of DPN. Multifactorial risk factor
reduction, targeting glycaemia, blood pressure and lipids can reduce the
progression of DPN and AN. Treatment of painful DPN reduces painful
symptoms by about 50% at best, but there is limited efficacy with any single
agent. This reflects the complex aetiology of painful DPN and argues for
improved clinical phenotyping with the use of targeted therapy, taking into
account co-morbid conditions such as anxiety, depression and sleep
disturbance.
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Diagnosing diabetic peripheral neuropathy: too little 
too late
The early diagnosis and monitoring of diabetic peripheral neu-
ropathy (DPN) are recommended by both the Toronto con-
sensus1 and the more recent American Diabetes Association 
(ADA) position statement on DPN2. They recommend the pres-
ence of at least one symptom or sign of neuropathy and abnor-
mal neurophysiology for the diagnosis of DPN. Symptom 
questionnaires, composite neurological scores and quantitative 
sensory testing (QST) may be used to diagnose DPN (Table 1). 
The neuropathy disability score3, a composite measure of 
neurological deficits (based on Achilles tendon reflexes, 120-Hz 
vibration, temperature and pin-prick sensation); Toronto Clini-
cal Neuropathy Score4; and the Michigan Neuropathy Screening 
Instrument5 are validated neurological scores of clinical DPN. 
Although these tests are adequate tools to screen for DPN, they 
lack the sensitivity to assess change in clinical trials of relatively 
short duration (12–24 months). Yet they continue to be advo-
cated as measures of efficacy, despite serial failure to show 
benefits in clinical trials of DPN.
QST6 is a painless, non-invasive means to diagnose small and 
large fibre dysfunction and is based on impaired thermal, pain 
and vibration perception, respectively (Table 1). Elevated vibra-
tion perception threshold is a risk factor for foot ulceration and 
lower-extremity amputation7 but is a subjective test8. Light touch 
can be assessed by using the 10-g monofilament and is com-
monly advocated as a screening tool for DPN, although it can 
only detect advanced neuropathy9 and those at increased risk of 
amputation10. Diagnosing established DPN is akin to ‘closing the 
stable door after the horse has bolted’.
Nerve conduction studies assess large fibre function and are 
currently advocated as the gold standard for a definite diagnosis 
of DPN11. The typical electrophysiological findings in DPN are 
reduced amplitude of the compound muscle action potential, 
slower nerve conduction velocity, prolonged F-wave latency 
and an altered H-reflex. They are particularly useful for 
differentiating from other or concomitant neuropathies such as 
chronic inflammatory demyelinating polyneuropathy (CIDP)12. 
They are also advocated as a primary end-point to measure 
therapeutic effect but have equally failed in the majority of clinical 
trials of DPN13.
Thus, several caveats ought to be carefully considered when these 
tests are employed to assess change over time and the response 
to therapies. Although composite scores and QST are resource-
ful methods to assess neuropathy, they have poor sensitivity 
and reproducibility14 and low histopathological specificity15. 
They may be of value in large longitudinal cohort studies as 
opposed to individual patients or relatively small phase III 
clinical trials of short duration14. Nerve conduction studies can-
not assess small fibre neuropathy and have poor inter-rater 
reproducibility16, making multi-centre trials difficult17. Indeed, these 
measures have consistently failed to show meaningful improve-
ments in clinical trials of neuropathy18–20.
Intra-epidermal nerve density (IENFD) evaluation in skin biopsy 
offers an objective and more reproducible means to assess 
small nerve fibre pathology21. IENFD is reduced in pre-diabe-
tes22, predicts incident neuropathy23 and improves with lifestyle 
intervention24. Unlike neurophysiology, skin biopsy is not con-
founded by height and weight, although a gender- and age- 
dependent decline has been reported21. There are published 
guidelines on the use of skin biopsy to diagnose DPN25. 
However, wider adoption of skin biopsy is limited by cost, the 
need for a dedicated processing and assessment facility, and the 
risk of bleeding and infection following the procedure. Corneal 
confocal microscopy (CCM) is a powerful, non-invasive oph-
thalmic imaging end-point for DPN and other neuropathies26. 
CCM can be used to quantify small fibre pathology with high 
reproducibility27. Corneal c-fibres form the sub-basal nerve plexus 
and are highly metabolically demanding28 and hence vulner-
able even to transient and minor metabolic perturbation22. Recent 
Table 1. Common tests for the assessment of neuropathy.
Type of nerve Investigation Advantages and disadvantages
Large fibre Nerve conduction studies Gold standard 
Sensitive, specific, and reproducible and easily standardised 
Must be done by trained professional
Large and small fibres Neuropathy disability score Good predictor for risk of ulceration 
Subjective 
Does not detect sub-clinical large fibre damage
Small fibre Quantitative sensory testing Reproducible and reliable 
Subjective
Skin biopsy Gold standard for small fibre testing 
Reliable and reproducible 
Invasive procedure which needs specialised laboratory service
Corneal confocal 
microscopy
Rapid, reproducible, non-invasive 
Detects small fibre damage and tracks worsening and improvement in small  
phase 2b clinical trials 
Requires training to perform
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studies have established CCM values for the diagnosis29–31 and 
prediction32,33 of DPN on the basis of corneal nerve fibre density 
and length34–37. CCM has also shown corneal nerve regeneration 
in clinical trials before change in other US Food and Drug Admin-
istration (FDA)-accepted end-points (for example, neurophysiol-
ogy and skin biopsy), a finding which has important implications 
for clinical trial design13.
Disease modification for diabetic neuropathy
In the 2017 ADA position statement on diabetic neu-
ropathy, early recognition of DPN even in pre-diabetes is 
recommended2,38,39. There are no FDA-approved disease- 
modifying treatments for the management of DPN, and improved 
glycaemic control to prevent progression forms the mainstay 
of treatment. In type 1 diabetes mellitus (T1DM), improved 
glycaemic control can prevent the development and delay the 
progression of neuropathy40. However, in T2DM, there is lim-
ited evidence that improved glycaemic control can slow down 
the progression of neuropathy41–43. The EURODIAB IDDM 
(European Diabetes Centers Study of Complications in Patients 
with Insulin-dependent Diabetes Mellitus), which evaluated 
over 3000 patients with T1DM for a duration of 7 years, identi-
fied poor glycaemic control, elevated low-density lipoprotein 
(LDL) cholesterol and triglycerides, hypertension, obesity and 
smoking as risk factors for incident DPN44.
In patients with T1DM, treatment with an angiotensin-convert-
ing enzyme (ACE) inhibitor45 or in combination with a cal-
cium channel blocker46 has been shown to improve DPN in ran-
domised placebo-controlled trials47,48. Statins and fibrates have 
also been shown to prevent the development of DPN49,50 and 
have been associated with reduced diabetic foot infection51 and 
lower-extremity amputation52,53 and increased rate of foot ulcer 
healing54. Recent experimental studies advocate the use of 
combination therapies targeting several pathogenetic pathways as 
the most effective approach to the treatment of DPN55–57.
Painful diabetic peripheral neuropathy
Diagnosis of painful diabetic peripheral neuropathy
Painful diabetic peripheral neuropathy (PDPN) is a manifesta-
tion of small fibre damage58–60, characterised by burning pain and 
tingling with nocturnal exacerbation. It has a significant impact 
on the patient’s quality of life61–63 and can result in depression, 
anxiety and sleep disturbance62. Estimates of the prevalence 
of PDPN range from 14.0 to 65.3%61,64–69 (Figure 1). This 
difference can be attributed to different populations studied 
and different diagnostic methods. The prevalence of PDPN 
is higher in secondary compared with primary care70 and in 
patients with T2DM compared with T1DM61,64,71. It is impor-
tant to note that for a large proportion (12.5–61.5%) of patients, 
PDPN remains undiagnosed71,72. They are often unaware that 
the pain is related to diabetes and do not report it to their 
clinician72. Older age, longer duration of diabetes, and the presence 
of DPN increase the risk for PDPN61,64–66,68; and obesity61,65,70,71, 
low physical activity24,67, smoking64,70, poor glycaemic control73,74, 
low high-density lipoprotein (HDL) cholesterol61, and raised LDL 
cholesterol, triglycerides and creatinine67 are independent risk 
factors for PDPN. Early diagnosis and intervention may be the 
key, as a study of subjects with pre-diabetes showed that life-
style intervention reduced neuropathic symptoms and improved 
small fibre function and structure24. Therefore, actively screen-
ing patients for PDPN, particularly those at high risk, should 
allow early identification and symptom relief but may also enable 
timely disease modification.
There are several screening tests that distinguish nociceptive and 
neuropathic pain. The most common screening tests for PDPN 
are the Douleur Neuropathique 4 (DN4) questionnaire75, the 
Figure 1. Prevalence of painful diabetic peripheral neuropathy (PDPN) reported from different countries ranges from 14.0 to 65.3%61,64–69.
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Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) 
pain scale76 and the Neuropathic Pain Questionnaire (NPQ)77. 
The DN4 is composed of 10 questions (seven symptoms and three 
neurological deficits), and a score of at least 4 has a high sensi-
tivity (83%) and specificity (90%) for PDPN78. The LANSS pain 
scale is composed of five questions on symptoms and two on 
neurological deficits, and a score at least 12 has a 85% sensitivity 
and 80% specificity for PDPN76. The NPQ contains 10 questions 
on quality of pain and two on change in sensation77 and detects 
PDPN with 74.7% sensitivity and 77.6% specificity.
Treatment of painful diabetic peripheral neuropathy
There is no evidence that improvement in glycaemic control 
improves PDPN; indeed, where rapid and large reductions in 
HbA1c may precipitate an acute painful neuropathy, the opposite 
is true79. The traditional approach to managing PDPN is to try 
different therapies until one works (with minimal side effects). 
However, improved clinical phenotyping and targeting of thera-
pies based on underlying mechanism(s) may result in better 
outcomes80. Detailed phenotyping using QST suggests that 
in patients with an irritable nociceptor compared with a non- 
irritable nociceptor phenotype, there is a better response to 
oxcarbazepine, with a number needed to treat (NNT) of 3.9 
compared with 6.9 in those with the non-irritable nociceptor81. 
Identifying abnormalities in rate-dependent depression (RDD), 
a marker of altered descending inhibitory modulation of pain, 
may also help to identify patients who will respond optimally 
to selective norepinephrine reuptake inhibitors for example, 
duloxetine82.
Tricyclic anti-depressants (TCAs) modulate pain and have anal-
gesic efficacy by indirectly modifying the opioid system in the 
brain and via serotonergic and noradrenaline neuromodulation, 
amongst other mechanisms83–85. Amitriptyline is the most 
commonly used TCA in PDPN, despite not having a label for 
its treatment. In a systematic review, Moore et al.86 evaluated 17 
studies with 1342 participants and concluded that study qual-
ity was modest, and most studies had a high risk of bias due to 
the small participant numbers86. Two serotonin and norepine-
phrine reuptake inhibitors (SNRIs) are recommended for PDPN: 
duloxetine and venlafaxine. They exert their effect via inhibit-
ing serotonin and noradrenaline reuptake with potentiation of 
descending inhibitory pathways87. A Cochrane review including 
eight randomised controlled trials (n = 2728) showed that duloxe-
tine 60 mg daily was superior to placebo, and the NNT was 588. 
Pregabalin also has FDA approval for PDPN on the basis of a 
number of randomised controlled trials (RCTs)89–91. Snedecor 
et al. undertook a comparative meta-analysis of a number of 
agents to treat PDPN and found pregabalin to be the most 
efficacious in reducing Visual Analogue Scale (VAS) pain 
scores92. Duloxetine and pregabalin are both considered first-
line therapy by National Institute for Clinical Excellence (NICE) 
and the 2017 ADA position statement2,93. Mirogabalin has also 
recently shown efficacy and good tolerability in a phase II 
and two phase III clinical trials in PDPN94–96. Tramadol has an 
opioid plus SNRI effect. A Cochrane Collaboration review found 
that the efficacy of tramadol in neuropathic pain was determined 
in small, inadequately sized studies with a risk of bias97, although 
a meta-analysis showed an NNT of 4.4. Tapentadol extended-release 
has also shown efficacy in a number of randomised clinical trials 
and is recommended by the FDA in PDPN98–101.
The COMBO-DN (Combination versus Monotherapy of prega-
balin and duloxetine in Diabetic Neuropathy) study compared 
monotherapy with a combination of duloxetine and pregabalin102. 
The pain outcomes between combination (duloxetine 60 mg 
daily plus pregabalin 300 mg daily) and high-dose monotherapy 
(duloxetine 120 mg daily or pregabalin 600 mg daily) were 
comparable102. In an exploratory post-hoc analysis, high-dose 
monotherapy was more favourable in patients with severe pain, 
whereas combination therapy was more beneficial in patients 
with mild to moderate pain103. In a double-blind RCT with 
a parallel-group design, analgesic efficacy was found to be 
comparable between amitriptyline, duloxetine and pregabalin104.
In patients presenting with PDPN, the key is to provide 
symptom relief, but we would argue that this also represents a 
window of opportunity for risk factor reduction to limit DPN 
progression. For symptom relief, pregabalin, gabapentin, duloxe-
tine or amitriptyline can be used first line, and if they are not 
working or have limited effectiveness because of side effects, 
then a second-line agent or tramadol can be added in combination 
(Table 2). Topical therapies such as a glyceryl trinitrate 
(GTN) spray105 or patch106 applied to the feet can be considered 
and give a favourable NNT of about 4107,108. There is an evolving 
argument that the future management of PDPN will follow a 
more personalised approach using markers such as RDD109, 
CCM110 and genomics111–113 to identify specific mechanisms in 
patients who will respond better to targeted therapies.
Cardiac autonomic neuropathy
The Toronto consensus panel defined cardiac autonomic neu-
ropathy (CAN) as the impairment of cardiovascular autonomic 
control in patients with diabetes mellitus after the exclusion of 
other causes114. CAN occurs in subjects with impaired glucose 
tolerance (IGT), and abnormal cardiovascular autonomic reflex 
tests (CARTs) have been reported in up to 7% of patients at diag-
nosis of T1DM and T2DM115–117 with the prevalence increasing 
to 30% (Diabetes Control and Complications Trial/Epidemiology 
of Diabetes Interventions and Complications, or DCCT/EDIC) 
after 14 years of T1DM118,119 and in other studies to 70% after 
15 years120. CAN is an independent risk factor for mortality114 
and was the strongest risk factor for all-cause mortality in 
the EURODIAB study (T1DM) and an independent risk 
factor for mortality in the Action to Control Cardiovascular Risk 
in Diabetes (ACCORD) study (T2DM)121,122. A meta-analysis of 
15 longitudinal studies reported an association between CAN 
and increased mortality123. A meta-analysis of 12 studies identi-
fied silent myocardial ischaemia (SMI) in 20% of patients with 
CAN compared with 10% in those without CAN117. CAN is also 
associated with left ventricular dysfunction124,125 and independently 
predicts the progression of diabetic nephropathy126.
Diagnosis of cardiac autonomic neuropathy
Screening for CAN is recommended at diagnosis in patients 
with T2DM and after 5 years for those with T1DM. Signs and 
symptoms of CAN should be assessed in patients with 
microvascular complications and in patients with hypoglycaemia 
unawareness2,127. The diagnosis of CAN includes the documentation 
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of the symptoms and signs (Table 3), but there is a weak correla-
tion between symptoms and autonomic deficits120,140 and symptoms 
may be subtle like intermittent palpitations and exercise intol-
erance. CAN may initially be asymptomatic with the only sign 
being decreased heart rate variability with deep breathing, 
which can progress to a resting tachycardia (>100 bpm). In 
patients who are symptomatic (resting tachycardia with a history 
of poor glucose control) or where the diagnosis of CAN is very 
likely, the ADA position statement advises no additional testing2. 
It is important to exclude other causes such as idiopathic ortho-
static hypotension (OH), syncope and postural orthostatic 
tachycardia syndrome (POTS)141. CARTs includes heart rate 
response to deep breathing, standing and the Valsalva manoeuvre.
Management of autonomic neuropathy
Poor glycaemic control and longer diabetes duration are estab-
lished risk factors for CAN42,118,119. The DCCT showed that 
intensive glycaemic control in patients with T1DM reduced the 
development of CAN by 45%118. Hypertension, obesity, hyperlipi-
demia and smoking have also been implicated in the development 
of CAN42,117,120,142–144, and the Steno-2 trial showed that intensified 
multifactorial treatment in patients with T2DM reduced the risk 
of CAN progression by 68%145,146. There are no FDA-approved 
disease-modifying treatments to reverse CAN. A small early 
study found favourable effects of alpha-lipoic acid (ALA) on 
CAN147, however, more recently a study to evaluate triple anti- 
oxidant therapy (allopurinol (300 mg once daily), ALA (600 mg 
twice daily) and nicotinamide (750 mg twice daily)) in patients 
with mild to moderate CAN found no benefit148.
Orthostatic hypotension
Symptoms of OH occur on standing and include light-headedness, 
weakness, faintness and syncope. OH is defined by a blood 
pressure decrease on standing of greater than 20/10 mm Hg (a 
decrease of greater than 30/15 for those with blood pressure of 
greater than 150/90) without an appropriate increase in heart 
rate (<15 bpm)149. Treatment of OH involves a review of medica-
tion, fluid and salt repletion and encouragement of physical activ-
ity and exercise to avoid deconditioning150,151. Fludrocortisone 
is not FDA-approved for OH. It works through sodium retention 
and constriction of partially denervated blood vessels, but there 
are concerns over supine hypertension, hypokalaemia, conges-
tive cardiac failure and peripheral oedema152. Both midodrine 
and droxidopa are approved by the FDA for the treatment of 
symptomatic neurogenic OH153.
Gastroparesis
Gastroparesis is defined as the delayed removal of stomach 
contents in the absence of a physical obstruction154. Gastric 
emptying should be assessed with scintigraphy 4 hours after food 
intake of digestible solids at 15-min intervals. Dietary modifica-
tion with frequent small meals and prokinetics are recommended 
to increase gastric motility. Metoclopramide is the only FDA- 
approved drug for the treatment of gastroparesis. However, 
limited efficacy and the risk of tardive dyskinesia have led 
the FDA and European Medicines Agency to advise use for a 
maximum of 5 days. New therapies are being investigated and 
include motilin receptor agonists, ghrelin receptor agonists, 
and neurokinin receptor antagonists. Mechanical options for 
intervention include transpyloric stenting, gastric electrical 
Table 3. Symptoms and signs of diabetic autonomic neuropathy.
Cardiac autonomic neuropathy 
•  Resting tachycardia or fixed heart rate or both 
•  Loss of circadian rhythm of blood pressure 
•  Increase in nocturnal systolic blood pressure compared with daytime 
•  Orthostatic hypotension 
•  Exercise intolerance 
•  Syncope and light headedness 
•  Intra-operative cardiovascular lability 
•  ‘Silent ischemia’ and ‘painless’ myocardial infarction 
•  Arrhythmias 
 
•  Urogenital autonomic neuropathy 
Bladder dysfunction 
•  Increase in frequency and urgency particularly during the night 
•  Urinary hesitancy and weak stream 
•  Dribbling of urine and involuntary urination 
•  Urinary incontinence 
Sexual dysfunction 
•  Male: erectile dysfunction, decreased libido and abnormal ejaculation 
•  Female: decreased sexual desire and arousal, increased pain during intercourse and inadequate lubrication 
 
Gastrointestinal autonomic neuropathy 
•  Nausea/vomiting 
•  Bloating 
•  Inability to eat a full meal 
•  Profuse and watery diarrhoea (nocturnal) 
•  Constipation
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stimulation, and gastric per-oral endoscopic myotomy; in severe 
intractable gastroparesis, laparoscopic pyloroplasty or gastrectomy 
may be options155.
Diabetic diarrhoea
Diabetic diarrhoea is a troublesome gastrointestinal complication 
which is characterised by watery painless diarrhoea, particularly 
at night. Other causes of diarrhoea must be excluded, especially 
therapy with metformin which is often overlooked, and pan-
creatic exocrine insufficiency (faecal fat of greater than 6 g/72 
hours). Pharmacological therapies include antidiarrhoeal agents 
(for example, Lomotil or Imodium), antibiotics (tetracycline or 
metronidazole) to eradicate bacterial overgrowth, somatosta-
tin analogues (octreotide), and selective serotonin 5-hydroxy 
tryptamine type 3 (HT3) receptor antagonists (Ramosetron)156,157.
Bladder disturbance
Bladder dysfunction may occur in up to 50% of patients with 
diabetes due to urogenital autonomic neuropathy141. The earli-
est manifestation includes increased initiating threshold for the 
micturition reflex followed by decreased detrusor activity and 
incomplete bladder emptying. Treatment includes suprapubic pres-
sure, antimuscarinic medication (oxybutynin 5–30 mg 3 times a 
day; tolterodine 2–8 mg twice a day) for detrusor hyperreflexia 
and parasympathomimetic medication to reduce detrusor contrac-
tility, and intermittent self-catheterisation2. It is important to note 
that none of the medications are FDA-approved for neurogenic 
bladder and they have approval only for non-neurogenic overactive 
bladder or other lower urinary tract symptoms.
Erectile dysfunction
Erectile dysfunction (ED) is a common manifestation in men 
with diabetes141. It may be three times more prevalent, occur 10 
to 15 years earlier and is more severe and less responsive to treat-
ment compared with those without diabetes158. ED is associated 
with a higher HbA1c, presence of metabolic syndrome, hyper-
tension, atherogenic dyslipidemia, lower estimated glomerular 
filtration rate, higher albumin/creatinine ratio and more severe 
small fibre neuropathy in men with T1DM159–161. Sexual 
dysfunction is also more common in women with diabe-
tes, and 47% of women with diabetic neuropathy had sexual 
dysfunction162. Reduced sexual arousal, decreased lubrication and 
painful intercourse are the most common symptoms of sexual 
dysfunction in females with diabetes. Recent recommendations 
include active smoking cessation (improves ED by about 30%), 
treatment of those with testosterone deficiency and treatment 
with statins. 5-phosphodiesterase inhibitors, intra-cavernosal and 
transurethral prostaglandins, and penile implants can be used 
for more severe cases163–165. There is about a 50% non-responder 
rate in patients with diabetes as they are less likely to respond 
to PDE5 inhibitors166. Additional modalities such as low-inten-
sity extracorporeal shock wave therapy show promise167–169 
but require larger and better designed clinical trials. There are 
several explanations for the lack of response166, but it may also 
reflect a more severe neurogenic component to ED in these 
patients159. Indeed, in a recent study, the assessment of 
nocturnal penile tumescence and rigidity, which reflects predomi-
nantly neurogenic abnormalities, had an area under the curve 
(AUC) of 0.860 in differentiating sildenafil responders from 
non-responders170.
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